Core Insights - Pfizer Inc. announced positive topline progression-free survival results from Cohort 3 of the pivotal BREAKWATER trial, which evaluated BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and FOLFIRI in patients with previously untreated metastatic colorectal cancer with a BRAF V600E mutation [1] Group 1 - The BRAFTOVI regimen demonstrated statistically significant results in the trial [1]

Core Insights - Pfizer Inc. announced positive results from Cohort 3 of the BREAKWATER trial, which evaluates the efficacy of BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFIRI in patients with untreated metastatic colorectal cancer (mCRC) with a BRAF V600E mutation [1] Group 1 - The BREAKWATER trial is pivotal for assessing the BRAFTOVI combination regimen [1] - The study focuses on patients with previously untreated metastatic colorectal cancer [1] - The combination includes BRAFTOVI, cetuximab (marketed as ERBITUX®), and FOLFIRI (fluorouracil, leucovorin, and irinotecan) [1]